Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 19, 2002
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assayKatleen De Preter, Frank Speleman, Valérie Combaret, et al.
Oncology Letters|February 8, 2021
Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cellsCorey D Chan, Emma J Haagensen, Hayeit A Tensaout, et al.
Chemical Biology & Drug Design|November 13, 2014
Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping ApproachAndrey Zaytsev, Barry Dodd, Matteo Magnani, et al.
International Journal of Cancer|December 12, 2018
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastomaLindi Chen, Fabio Pastorino, Philip Berry, et al.
Oncotarget|June 22, 2016
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationCatherine J Drummond, Arman Esfandiari, Junfeng Liu, et al.
Medchemcomm|October 1, 2013
Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data fileTim J Blackburn, Shafiq Ahmed, Christopher R Coxon, et al.
Oncotarget|November 6, 2015
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaAshleigh Herriott, Susan J Tudhope, Gesa Junge, et al.
British Journal of Cancer|January 27, 2023
Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulationBassier Zadran, Praveen Dhondurao Sudhindar, Daniel Wainwright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaJane Carr-Wilkinson, Kieran O'Toole, Katrina M Wood, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2011
MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinonesAnna F Watson, Junfeng Liu, Karim Bennaceur, et al.
Pageof 8